Progressing lesions of 25 patients with GISTs refractory to ripretinib were sequenced for KIT resistance mutations. Resistant genotypes were validated and characterized using novel cell line models ...
An illustration shows the structure of an inhibitor bound to the active site of membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase. An inhibitor bound to the active site of ...
Early-phase clinical trials involving PIM-1 kinase inhibitors look promising. In the evolving landscape of myelofibrosis (MF) ...
Inform future clinical development plans, further establishing elraglusib as a potential backbone therapy in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results